GH · Guardant Health, Inc. · Stock research

Current Thesis

The earnings binary resolved on 30 July, and the fortnight since has been spent re-marking analysts rather than re-rating the company. Q2 2026 revenue printed $334.978M against $314.226M consensus, and FY2026 guidance moved to $1.340–1.360B from the $1.300–1.320B set on 7 May — a floor above the $1.314B the Street carried into the print. A second target wave followed on 3–4 August: Stifel $180, Morgan Stanley $185 (from $175), Piper Sandler $193 (from $135), Stephens $195 (from $170). Like the 31 July cluster that topped at TD Cowen's $210, none of it cleared the $215 Citigroup published on 8 July.

So the revenue line has stepped up twice this year while the sell-side ceiling has been fixed for five weeks. Price reflects that split: the 2026-08-14 close of $157.21 sits 7.9% under the $170.77 52-week high, RSI(14) at 60.6 after a +65.6% three-month run. The shelf prospectus filed 30 July remains live with no publicly announced priced takedown as of 16 August, and the only dated company event before the Q3 report is a fireside chat on 15 September.

Bullish and bearish views on Guardant Health, Inc.

The model's bull view on Guardant Health, Inc. (GH), in brief: Guidance raised (2026-07-30): FY2026 to $1.340–1.360B from $1.300–1.320B, versus $1.314B consensus. The bear view: The shelf is live and unpriced. Filed 2026-07-30 with size not disclosed, the same day as the print. Precedent for how this company uses it: on 2025-11-05 Guardant priced an upsized offering of 3,333,333 shares at $90.00 (~$300M), books run by Goldman Sachs, Jefferies, Leerink… Both cases follow in full.

Bull Case

• Guidance raised (2026-07-30): FY2026 to $1.340–1.360B from $1.300–1.320B, versus $1.314B consensus. The specific bear scenario carried in the prior note — a range reaffirmed rather than lifted — did not occur.
• Revenue beat (2026-07-30): Q2 $334.978M against $314.226M consensus, following Q1 2026 revenue of $302M, +48% YoY (reported 2026-05-07).
• Nine target raises across five sessions (2026-07-31 and 2026-08-03/04): TD Cowen $210, RBC $200, Mizuho $200, JPMorgan $195, BTIG $195, then Stephens $195, Piper Sandler $193, Morgan Stanley $185, Stifel $180 — every rating maintained rather than initiated. Piper's move from $135 to $193 was a single step.
• ACS guideline inclusion (2026-05-27): Shield added to the American Cancer Society colorectal screening guidelines; shares +9.0% that session. Guideline status is the precondition for payer coverage and primary-care ordering.
• Expanded FDA approval (2026-05-20): Guardant360 Liquid CDx approved, widening the comprehensive genomic profiling franchise that sits alongside Shield.
• A dated venue inside a thin quarter (2026-09-15): the Morgan Stanley 24th Annual Global Healthcare Conference fireside chat, announced 2026-07-29, is the one scheduled opportunity for Shield volume or payer commentary before late October.

Bear Case

• The shelf is live and unpriced. Filed 2026-07-30 with size not disclosed, the same day as the print. Precedent for how this company uses it: on 2025-11-05 Guardant priced an upsized offering of 3,333,333 shares at $90.00 (~$300M), books run by Goldman Sachs, Jefferies, Leerink and Guggenheim. A takedown can be priced without advance notice.
• The bottom line missed and is large. Adjusted EPS $(0.42) against $(0.41) consensus; GAAP net loss of $120.14M in Q2 2026. Valuation rests on the forward revenue line because there is no trailing earnings multiple.
• The target ceiling has not moved since 2026-07-08. Citigroup's $215 has stood through two post-print raise clusters. Roughly a dozen covering firms — Citigroup, RBC, Mizuho, JPMorgan, TD Cowen, BTIG, Stephens, Piper Sandler, Morgan Stanley, Stifel, Evercore, Wolfe — have already converted to positive ratings, which thins the pool of remaining upgrade bids.
• Price is below its high with an empty calendar. $157.21 on 2026-08-14 versus the $170.77 52-week high, with no company-issued number due until the Q3 print.
• Guideline placement is second-line. ACS recommends Shield for patients who decline or have not completed stool testing or colonoscopy, which caps the ordering funnel below a first-line screening framing.

Setup & Price Structure

• Reference levels: last close $157.21 (2026-08-14); 52-week high $170.77, 7.9% above; RSI(14) 60.6; three-month return +65.6%.
• Structure below: the 3 June breakout shelf near $128 is the floor the July–August re-rate was built from; the pre-ACS base near $108 is the level from which the entire 2026 move originates.
• The narrative is maturing. The narrative is still producing new company facts (guidance raise 2026-07-30) and new sell-side marks (2026-08-04), so it is not dead and not yet late-cycle mainstream. But the second post-print target wave failed to extend the ceiling set on 2026-07-08, and price has traded under the 52-week high since. New attention is arriving as target catch-up rather than as new coverage.
• Crowding observables, stated as observables: two price-target clusters inside five sessions; one raise of 43% in a single step (Piper Sandler, 2026-08-04) with no accompanying rating change; a live shelf registration filed into a +65.6% three-month move; no scheduled company event between 2026-08-16 and 2026-09-15.

Catalyst Calendar (next 30 days)

• 2026-09-15 — Morgan Stanley 24th Annual Global Healthcare Conference, fireside chat 7:45 a.m. ET, New York (announced 2026-07-29). The only dated management appearance before the Q3 report.
• ~2026-10-29 (est.), outside the 30-day window — Q3 2026 results. The next scheduled test of whether the FY2026 range moves a third time.

Elapsed catalysts

• Undated, live since 2026-07-30 — shelf takedown pricing. Size, price and any discount to the prevailing market determine whether the 30 July filing is optionality or a supply event. (passed 27d ago)

What Would Change Our Mind

The structure carrying this is the 3 June breakout shelf; the July–August re-rate is stacked directly on it. A weekly close below $128 forfeits that shelf, and a weekly close below $108 would give back the pre-ACS base and with it the guideline-driven leg entirely.

Three non-price conditions would matter as much. First, a priced takedown off the 30 July shelf at a discount to market would convert a filed option into realised supply at prices set by a two-and-a-half-month advance. Second, an FY2026 range held at $1.340–1.360B at the Q3 print rather than lifted would end the consecutive-raise pattern that the current multiple assumes. Third, if 15 September passes with no new Shield volume, payer or channel datapoint while $215 remains the street-high target set on 8 July, the narrative has run out of both scheduled information and sell-side headroom until late October.

Correlation Notes

• Moves with the unprofitable diagnostics and tools complex — EXAS, NTRA, TEM — on funding-conditions and rate moves that hit cash-burning, long-duration revenue stories independent of Guardant's own numbers.
• Quest Diagnostics (DGX) is simultaneously a Shield distribution channel and a lab competitor; DGX channel commentary is a third-party read on Shield draw volume that Guardant does not control.
• Direct competitive read-across to Exact Sciences and privately held Freenome on blood-based colorectal sensitivity and specificity data; a competing readout at or above Shield's performance is a Guardant-specific de-rating risk rather than a sector one.
• Drivers are guideline, payer and FDA decisions — not AI capex, semiconductor cycles or consumer demand, so the name does not track the index leadership that has led 2026 tape.